Vaxxinity, Inc. Stock Price, News & Analysis

Vaxxinity (Nasdaq: VAXX) announced that CEO Mei Mei Hu will present at two investor conferences in November 2022. The Jefferies London Healthcare Conference will run from November 15-17, with Hu speaking on November 17 at 8:00 a.m. GMT. The Evercore ISI HealthCONx Conference takes place from November 29 to December 1, with Hu presenting on December 1 at 12:35 p.m. ET. Live webcasts will be available on the company’s website, with replays accessible for 90 days. Vaxxinity focuses on groundbreaking immunotherapeutic vaccines for chronic diseases.

Vaxxinity (Nasdaq: VAXX) has completed enrollment for its global Phase 3 trial of UB-612, a COVID-19 vaccine intended to serve as a heterologous booster. Topline results are expected in 4Q22. The company has also initiated a rolling submission for provisional approval from Australia's Therapeutic Goods Administration following prior approval determination. UB-612 aims to enhance immunity against various COVID-19 variants and has shown promise in earlier trials with ~4000 participants, reporting well-tolerated results and robust immune responses.

Vaxxinity, Inc. (Nasdaq: VAXX) has initiated its Phase 1 clinical trial for UB-313, a novel vaccine targeting calcitonin gene-related peptide (CGRP) for migraine prevention. The study, enrolling about 40 healthy volunteers at UZ Leuven in Belgium, aims to assess safety, tolerability, and immunogenicity. This milestone underscores Vaxxinity's commitment to expanding its innovative peptide vaccine platform into chronic conditions. The potential of UB-313 to provide longer-lasting relief and affordable treatment is a significant advancement for migraine patients globally.

Vaxxinity, Inc. (Nasdaq: VAXX) announced the initiation of a rolling submission to the UK’s MHRA for conditional marketing authorization of its UB-612 COVID-19 vaccine, aimed at serving as a heterologous boost. Currently in a Phase 3 trial, UB-612 has shown promise in earlier trials with over 4,000 participants, demonstrating good tolerability and inducing strong immune responses against various SARS-CoV-2 variants. Vaxxinity expects to have topline results from the Phase 3 trial by Q4 2022, which could facilitate global access to UB-612, particularly in low and middle-income countries.

DALLAS, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, a biotechnology company focused on immunotherapeutic vaccines, announces CEO Mei Mei Hu will present at two September investor conferences. The H.C. Wainwright 24th Annual Global Investment Conference is on September 12, 2022, from 10:00 a.m. to 10:30 a.m. ET. The Baird Global Healthcare Conference follows on September 13, 2022, from 3:10 p.m. to 3:40 p.m. ET. Both presentations will be available via webcast for 90 days. Vaxxinity aims to innovate in chronic disease treatment with peptide-based vaccines.

Vaxxinity, Inc. (Nasdaq: VAXX) announced its second-quarter 2022 financial results, reporting a net loss of $17.3 million, down from $26.9 million a year earlier. Key developments include the completion of patient dosing in the Phase 1 trial of UB-312 for Parkinson's and the initiation of enrollment for UB-313 targeting migraines. The company received $9.2 million in grant funding for the Phase 3 trial of UB-612 COVID-19 booster, expecting topline results in late 2022. Cash and equivalents were reported at $109.1 million, a decrease from $144.9 million since the end of 2021.

Vaxxinity, a biotechnology company on Nasdaq under the symbol VAXX, will have CEO Mei Mei Hu present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 11, 2022, at 1:00 p.m. ET. The presentation will be accessible via a live webcast on the company’s investor website, with a replay available for 90 days. Vaxxinity is focused on developing innovative peptide-based immunotherapeutic vaccines aimed at chronic diseases like Alzheimer’s, alongside a COVID-19 vaccine program. The company aims to improve global healthcare accessibility.

Vaxxinity, Inc. (Nasdaq: VAXX) has announced positive data demonstrating the effectiveness of its anti-PCSK9 vaccine candidate, VXX-401, in lowering LDL cholesterol in non-human primates. This significant advancement supports the company's aim to treat hypercholesterolemia and brings VXX-401 closer to a Phase 1 clinical trial set for early 2023. The vaccine showed a durable LDL reduction of 40-50% compared to placebo, validating its potential as a safer, more accessible treatment for cardiovascular diseases.

Vaxxinity, Inc. (Nasdaq: VAXX) presented promising preclinical data on its Tau-targeting vaccine candidates for Alzheimer's disease at the 2022 Alzheimer's Association International Conference. The research highlights the ability of these vaccines to induce antibodies that prevent Tau protein aggregation, a key factor in AD progression. The company aims to leverage its innovative peptide-based technology to create effective treatments for Alzheimer's and other chronic diseases. This aligns with Vaxxinity's ongoing development of its amyloid beta-targeting vaccine, UB-311, which has received FDA Fast Track designation.